Pharmaceutical company Arrakis Therapeutics has raised $75m to develop targeted RNA therapies. “We have built an end-to-end platform for the discovery of rSMs by creating or adapting tools that allow us to predict and validate the structure of RNA targets, locate druggable pockets, identify drug-like hits and conduct medicinal chemistry programs to improve potency, selectivity and safety,” Gilman said in a statement. The company, which was founded in 2013, said it had received a $125m investment from the US Department of Defense and that its first product would be an RNAi treatment for cancer. Arrakis said it would use the funding to bring at least one of its RNA therapies to clinical development and had a focus on oncology and other diseases. The company has $100m of funding.
Pharmaceutical company Arrakis Therapeutics has raised $75m to develop targeted RNA therapies. The company, which was founded in 2013, said it had received a $125m investment from the US Department of Defense and that its first product would be an RNAi treatment for cancer. Arrakis said it would use the funding to bring at least one of its RNA therapies to clinical development and had a focus on oncology and other diseases. The company has $100m of funding.